Clinical Trials and Research Studies
Phase 1
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
Learn MorePhase 1
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad
Learn MorePhase 1
A Phase 1 First-in-Human Open Label Dose Escalation Study of MGD009 A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART ) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses
Learn MorePhase 3
A Phase III Randomized Double-Blind Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric ad Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Learn More